Rosenow Felix, Winter Yaroslav, Leunikava Iryna, Brunnert Marcus, Joeres Lars, Sutphin Jessie, Boeri Marco, Smith Jasmine, Villani Flavio, Brandt Christian
Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
LOEWE Center for Personalized Translational Epilepsy Research, Goethe University, Frankfurt, Germany.
Epilepsia. 2022 Feb;63(2):451-462. doi: 10.1111/epi.17137. Epub 2021 Dec 17.
This study was undertaken to elicit patients' preferences for attributes characterizing antiseizure medication (ASM) monotherapy options before treatment consultation, and to explore the trade-offs patients consider between treatment efficacy and risks of side effects. Further objectives were to explore how treatment consultation may affect patient preferences, to elicit physicians' preferences in selecting treatment, and to compare patient and physician preferences for treatment.
This prospective, observational study (EP0076; VOTE) included adults with focal seizures requiring a change in their ASM monotherapy. Patients completed a discrete choice experiment (DCE) survey before and after treatment consultation. Physicians completed a similar survey after the consultation. The DCE comprised 12 choices between two hypothetical treatments defined by seven attributes. The conditional relative importance of each attribute was calculated.
Three hundred ten patients (mean [SD] age = 46.8 [18.3] years, 52.3% female) were enrolled from eight European countries, of whom 305 completed the survey before consultation and 273 completed the survey before and after consultation. Overall, this preference study in patients who intended to receive a new ASM monotherapy suggests that patient preferences were ordered as expected, with better outcomes being preferred to worse outcomes; patients preferred a higher chance of seizure freedom, lower risk of developing clinical depression, and fewer severe adverse events; avoiding moderate-to-severe "trouble thinking clearly" was more important than avoiding any other side effect. There were qualitative differences in what patients and physicians considered to be the most important aspects of treatment for patients; compared with patients, physicians had a qualitatively stronger preference for greater chance of seizure freedom and avoiding personality changes. Patients' preference weights were qualitatively similar before and after treatment consultation.
For patients, seizure freedom and avoiding trouble thinking clearly were the most important treatment attributes. Physicians and patients may differ in the emphasis they place on specific attributes.
本研究旨在了解患者在治疗咨询前对用于描述抗癫痫药物(ASM)单一疗法选项的属性的偏好,并探讨患者在治疗效果和副作用风险之间所考虑的权衡。进一步的目标是探讨治疗咨询如何影响患者的偏好,了解医生在选择治疗方法时的偏好,并比较患者和医生对治疗的偏好。
这项前瞻性观察性研究(EP0076;VOTE)纳入了需要改变ASM单一疗法的局灶性癫痫成年患者。患者在治疗咨询前后完成了一项离散选择实验(DCE)调查。医生在咨询后完成了一项类似的调查。DCE包括在由七个属性定义的两种假设治疗方法之间进行12次选择。计算了每个属性的条件相对重要性。
从八个欧洲国家招募了310名患者(平均[标准差]年龄=46.8[18.3]岁,52.3%为女性),其中305名在咨询前完成了调查,273名在咨询前后都完成了调查。总体而言,这项针对打算接受新ASM单一疗法的患者的偏好研究表明,患者的偏好符合预期顺序,较好的结果优于较差的结果;患者更喜欢癫痫发作自由度更高、临床抑郁风险更低以及严重不良事件更少;避免中度至重度“思维清晰障碍”比避免任何其他副作用更为重要。患者和医生认为对患者治疗最重要的方面存在质的差异;与患者相比,医生在癫痫发作自由度更高和避免人格改变方面有质的更强偏好。治疗咨询前后患者的偏好权重在质上相似。
对患者来说,癫痫发作自由度和避免思维清晰障碍是最重要的治疗属性。医生和患者在对特定属性的重视程度上可能存在差异。